Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)

Lundbeck

Status and phase: Completed; Phase 3

Conditions: Insomnia

Treatments: Drug: MK0928, gaboxadol / Duration of Treatment - 1 year; Drug: Comparator: placebo / Duration of Treatment -1 year

Study type: Interventional

Funder types: Industry

Identifiers

NCT00095069

MK0928-003

2004_086

0928-003

Details and patient eligibility

About

The purpose of this trial is to study the safety and effectiveness of MK0928 for adults with insomnia.

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diagnosis of insomnia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind